Therma Bright Secures an Initial Limited Exclusive U.S. Marketing and Distribution Contract for Its Consumer Products with Global Wellness Products LLC
Therma Bright Inc (TSXV: THRM) (OTCQB: TBRIF) has secured an exclusive U.S. marketing and distribution contract with Global Wellness Products , a subsidiary of Image Protect, Inc. (OTC Pink: IMTL), for its consumer product devices.
The partnership will initially focus on marketing the InterceptCS cold sore prevention device, followed by the rollout of other products including the Benepod hot-and-cold pain therapy device and TherOZap insect bite therapy device. This strategic move comes after Therma Bright's 2024 focus on promoting their Venowave product following permanent HCPCS code receipt.
The agreement targets the global cold sore treatment market, which was valued at USD$1.02 Billion in 2024 and is projected to reach USD$1.57 billion by 2031, according to Coherent Research.
Therma Bright Inc (TSXV: THRM) (OTCQB: TBRIF) ha ottenuto un contratto esclusivo di marketing e distribuzione negli Stati Uniti con Global Wellness Products, una sussidiaria di Image Protect, Inc. (OTC Pink: IMTL), per i suoi dispositivi di consumo.
La partnership si concentrerà inizialmente sul marketing del dispositivo per la prevenzione dell'herpes labiale InterceptCS, seguito dal lancio di altri prodotti tra cui il dispositivo per la terapia del dolore caldo e freddo Benepod e il dispositivo per la terapia delle punture di insetto TherOZap. Questa mossa strategica arriva dopo che Therma Bright ha posto nel 2024 l'accento sulla promozione del proprio prodotto Venowave, dopo aver ricevuto il codice HCPCS permanente.
L'accordo mira al mercato globale dei trattamenti per l'herpes labiale, che è stato valutato 1,02 miliardi di dollari USA nel 2024 e si prevede raggiungerà 1,57 miliardi di dollari USA entro il 2031, secondo Coherent Research.
Therma Bright Inc (TSXV: THRM) (OTCQB: TBRIF) ha obtenido un contrato exclusivo de marketing y distribución en EE. UU. con Global Wellness Products, una subsidiaria de Image Protect, Inc. (OTC Pink: IMTL), para sus dispositivos de productos de consumo.
La asociación se centrará inicialmente en el marketing del dispositivo de prevención de herpes labial InterceptCS, seguido por el lanzamiento de otros productos, incluyendo el dispositivo de terapia de dolor caliente y frío Benepod y el dispositivo de terapia para picaduras de insectos TherOZap. Este movimiento estratégico llega después de que Therma Bright se haya enfocado en 2024 en promover su producto Venowave tras recibir el código HCPCS permanente.
El acuerdo tiene como objetivo el mercado global de tratamientos para el herpes labial, que fue valorado en 1.02 mil millones de dólares estadounidenses en 2024 y se proyecta que alcanzará los 1.57 mil millones de dólares estadounidenses para 2031, según Coherent Research.
Therma Bright Inc (TSXV: THRM) (OTCQB: TBRIF)는 Global Wellness Products와 독점적인 미국 마케팅 및 유통 계약을 체결했습니다. 이 회사는 Image Protect, Inc. (OTC Pink: IMTL)의 자회사입니다.
이 파트너십은 처음에 InterceptCS 냉찜질 구내염 예방 장치의 마케팅에 집중하고, 이어서 Benepod 온냉 요통 치료 장치와 TherOZap 곤충 물기 치료 장치와 같은 다른 제품을 출시할 예정입니다. 이 전략적 결정은 Therma Bright가 2024년에 Venowave 제품을 홍보하는 데 집중한 후, 영구 HCPCS 코드를 수령한 후에 이루어졌습니다.
이 계약은 전 세계 구내염 치료 시장을 목표로 하며, 2024년에 10억 2천만 달러로 평가되었고, 2031년까지 15억 7천만 달러에 이를 것으로 예상되고 있습니다. 이는 Coherent Research에 따른 것입니다.
Therma Bright Inc (TSXV: THRM) (OTCQB: TBRIF) a obtenu un contrat exclusif de marketing et de distribution aux États-Unis avec Global Wellness Products, une filiale d'Image Protect, Inc. (OTC Pink: IMTL), pour ses dispositifs de produits de consommation.
Le partenariat se concentrera initialement sur le marketing du dispositif de prévention des boutons de fièvre InterceptCS, suivi du lancement d'autres produits, y compris le dispositif de thérapie par chaleur et froid Benepod et le dispositif de thérapie contre les piqûres d'insectes TherOZap. Ce mouvement stratégique intervient après que Therma Bright a mis l'accent en 2024 sur la promotion de son produit Venowave après avoir reçu le code HCPCS permanent.
Le contrat vise le marché mondial des traitements des boutons de fièvre, qui a été évalué à 1,02 milliard USD en 2024 et devrait atteindre 1,57 milliard USD d'ici 2031, selon Coherent Research.
Therma Bright Inc (TSXV: THRM) (OTCQB: TBRIF) hat einen exklusiven Marketing- und Vertriebsvertrag in den USA mit Global Wellness Products, einer Tochtergesellschaft von Image Protect, Inc. (OTC Pink: IMTL), für seine Verbraucherprodukte gesichert.
Die Partnerschaft wird sich zunächst auf das Marketing des InterceptCS-Geräts zur Vorbeugung von Lippenherpes konzentrieren, gefolgt von der Einführung weiterer Produkte, darunter das Benepod-Gerät zur Wärme- und Kältetherapie sowie das TherOZap-Gerät zur Behandlung von Insektenstichen. Dieser strategische Schritt erfolgt nach Therma Brights Fokus im Jahr 2024 auf die Förderung ihres Venowave-Produkts nach Erhalt des dauerhaften HCPCS-Codes.
Die Vereinbarung zielt auf den globalen Markt für Lippenherpesbehandlungen, der im Jahr 2024 mit 1,02 Milliarden USD bewertet wurde und voraussichtlich bis 2031 auf 1,57 Milliarden USD anwachsen wird, laut Coherent Research.
- Secured exclusive U.S. distribution agreement for consumer products
- Targeting USD$1.02 Billion global cold sore treatment market
- Expanding product distribution beyond Venowave to multiple consumer devices
- None.
National Distributor to Sell Cold Sore Prevention Device Through National Ecommerce Sales Through Direct to Consumer Marketing Efforts
Toronto, Ontario--(Newsfile Corp. - March 13, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce that the Company has secured an exclusive U.S. contract for its consumer product devices with national marketing and distribution partner Global Wellness Products LLC, a subsidiary of Image Protect, Inc. — a United States Corporation publicly traded under the symbol (OTC Pink: IMTL).
"We're pleased to team up with Global Wellness Products for the sale and delivery of our cutting-edge consumer products, with the first focus being our InterceptCS cold sore prevention device," shared Rob Fia, CEO of Therma Bright. "Initially, Global Wellness will focus on the cold sore prevention solution, and then roll-in our other products - Benepod hot-and-cold pain therapy device and TherOZap insect bite therapy device. In 2024, we spent a great deal of our sales and marketing efforts promoting and distributing our Venowave following receipt of the permanent HCPCS codes. Now we're increasing our efforts towards some of our other consumer products."
"We see great opportunity within the retail marketplace to introduce Therma Bright's consumer products, including the InterceptCS ™ cold sore prevention device," expressed Frank Casella, CEO of Global Wellness Products LLC. "This proven medical device addresses the growing global cold sore treatment market*, which in 2024 was estimated at USD
* Source: Per Coherent Research - the global cold sore treatment market was estimated at USD
About InterceptCS ™ Cold Sore Prevention Device
The InterceptCS™ Cold Sore Prevention System Is the First Product Clinically Proven and Approved For the Prevention Of Cold Sores. This Cold Sore Prevention System is comprised of an ergonomically designed hand-held unit and a disposable treatment activator, the activator is good for preventing one cold sore occurrence.
About Global Wellness Products
Global Wellness Products is the new division of Image Protect, Inc, and was created to be a premier leader in the health and wellness products space. With over 50 years of combined experience in the direct response consumer products sector, the principals and staff at Global Wellness Products are ready to make massive inroads into the multi-billion-dollar health and wellness industry. Learn more at: https://www.globalwellnessproducts.com/
About Therma Bright Inc.
Therma Bright develops and partners on cutting-edge diagnostic and medical device technologies that address key healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: www.thermabright.com.
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com
FORWARD-LOOKING STATEMENTS
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as future sales of Venowave and related technology as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/244375
FAQ
What is the value of the cold sore treatment market that TBRIF is targeting?
Which products will TBRIF distribute through Global Wellness Products ?
What is the scope of TBRIF's distribution agreement with Global Wellness Products?
How will TBRIF's InterceptCS device be marketed in the U.S.?
